Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01894477 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well treosulfan and fludarabine phosphate, with or without total body irradiation before donor stem cell transplant works in treating patients with myelodysplastic syndrome or acute myeloid leukemia. Giving chemotherapy, such as treosulfan and fludarabine phosphate, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and mycophenolate mofetil after the transplant may stop this from happening.

NCT ID: NCT01893619 Recruiting - Clinical trials for Chronic Fatigue Syndrome

Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome

immunoprop
Start date: June 2013
Phase: N/A
Study type: Observational

Observational study regarding the use of supplements in chronic fatigue syndrome patients

NCT ID: NCT01893164 Recruiting - Clinical trials for Cubital Tunnel Syndrome

Comparison of Different Surgical Treatments for Different Scales of Cubital Tunnel Syndrome

Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine which is the best surgery to treat different severity scales of cubital tunnel syndrome.

NCT ID: NCT01892644 Withdrawn - Clinical trials for Myelodysplastic Syndromes

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

DefeHEMY
Start date: May 2013
Phase: Phase 2
Study type: Interventional

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC. Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment. Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.

NCT ID: NCT01892371 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: November 12, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back (relapsed) or are not responding to treatment (refractory). Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving quizartinib with azacitidine or cytarabine may work better in patients with acute myeloid leukemia or myelodysplastic syndrome.

NCT ID: NCT01892254 Completed - Clinical trials for Polycystic Ovary Syndrome

Incretin Effect in PCOS Women

Start date: June 2013
Phase: Phase 4
Study type: Interventional

This study investigates the incretin effect in women with polycystic ovary syndrome (PCOS) before and after removal of their insulin resistance by metformin. The investigators' hypothesis is that insulin resistant women with PCOS have a reduced incretin effect and elevated glucagon responses as measured by a 75-g oral glucose tolerance test and isoglycemic i.v. glucose infusion. The investigators hypothesise that both can be improved when their insulin resistance is removed.

NCT ID: NCT01890837 Completed - Clinical trials for Irritable Bowel Syndrome

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.

NCT ID: NCT01890330 Recruiting - Metabolic Syndrome Clinical Trials

Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome

METCO-2013
Start date: July 2013
Phase: N/A
Study type: Interventional

MetS is an early stage of CVD and is an appropriate target for dietary interventions. MetS is a clustering of risk factors (abdominal obesity, elevated serum triglycerides, low HDL-cholesterol, hypertension, elevated fasting blood glucose) accompanied by low grade chronic inflammation, hepatic steatosis (fatty liver) and reduced vascular function. This study will investigate the effect of a 12 week intervention with canola oil versus the typical fat mixture in the Western diet on blood lipids, blood vessel function and MetS parameters. CVD risk will be assessed based on the profile of lipids and other factors in the blood as well using specialized equipment for non-invasive monitoring of blood vessel function.

NCT ID: NCT01887964 Completed - Metabolic Syndrome Clinical Trials

Effect of Resistant Starch (Type-4) on Metabolic Syndrome

Start date: March 2012
Phase: N/A
Study type: Interventional

Metabolic syndrome is a condition characterized by excess body weight, large waist circumference, high cholesterol and glucose in the blood, and hypertension. People with metabolic syndrome are at increased risk for heart diseases. Research shows benefits of regular fiber intake in metabolic syndrome. However, due to altered taste and texture of the high fiber foods, long term intake of fiber is a challenge for metabolic syndrome patients. This study is designed to find if blinded-substitution of regular wheat flour in domestic kitchen with wheat flour enriched by an adaptable type of fiber (resistant starch-4), minimizes metabolic syndrome symptoms. this special type of fiber is also obtained from wheat.

NCT ID: NCT01887834 Completed - Clinical trials for Irritable Bowel Syndrome

Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome

IBS
Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disorder that is estimated to affect 30% of the general population. IBS is characterized by abdominal pain and cramps, and bowel dysfunction such as diarrhea and bloating. The medicines that are currently used to help people with IBS are not as effective as we would like them to be. These medicines are usually only prescribed to reduce the pain of IBS and not actually treat the disorder itself. Recently, scientists have found that probiotics (beneficial bacteria that live inside humans) may help reduce the painful symptoms and diarrhea that are part of IBS. This research is being conducted to determine whether this particular combination of three probiotic bacteria (named Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum) will reduce the symptoms of severe IBS.